- Published: 29 July 2020 29 July 2020
By Ken W. Pung, Associate Attorney, Standley Law Group LLP
Dana-Farber Cancer Inst., Inc., v. Ono Pharm. Co.
2020 U.S. App. LEXIS 21704; 2020 U.S.P.Q.2D (BNA) 10775
Opinion by: Circuit Judge Alan Lourie
Patents at Issue
U.S. Patent Nos.: 7,595,048, 8,168,179, 8,728,474, 9,067,999, 9,073,994, and 9,402,899.
The facts of this case concern an inventorship dispute over methods of treating cancer by administering antibodies targeting PD-1 (receptor) and PD-L1 (ligand) interactions on T cells (a type of lymphocyte that develops in the thymus gland). The three scientists involved in this inventorship dispute are: Nobel Prize laureate Dr. Honjo (of Ono Pharm., herein “Ono”), Dr. Wood (of the Genetics Institute, now owned by Pfizer), and Dr. Freeman (of Dana-Farber).